Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383149 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase 2 study of Metastatic Pancreatic Cancer, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 9
- Study locations
NCT00383149: Completed Phase 2 study of Metastatic Pancreatic Cancer, sponsored by R-Pharm.
NCT00383149 is a Phase 2 study of Metastatic Pancreatic Cancer that has completed, run by R-Pharm. The registered enrollment target is 58 participants, below the 105-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (45% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00383149, a Phase 2 study of Metastatic Pancreatic Cancer, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.
Primary Outcome
The percentage of participants surviving at 6 months was defined as the number of treated participants who had not died prior to 6 months from the date of their first dose divided by the total number of treated participants.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Ixabepilone
Study Locations (9)
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University Of Miami - Miami
Michigan
- University Of Michigan - Ann Arbor
- Wayne State University - Detroit
District of Columbia
- Georgetn Univ Lombardi Can Ctr - Washington D.C.
Missouri
- Ellis Fischel Cancer Center - Columbia
South Carolina
- Cancer Centers Of The Carolinas - Greenville
Washington
- Seattle Cancer Care Alliance - Seattle
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00383149 record still lists
NCT00383149 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 105-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT00383149 lists 9 locations in 7 states (Florida, Michigan, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00383149 about?
NCT00383149 is a clinical study titled "A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer". The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.
What is the current status of trial NCT00383149?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2007-01. Estimated completion is 2009-06.
What conditions does trial NCT00383149 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT00383149?
The interventions under investigation include: Cetuximab (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00383149?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00383149 being conducted?
This trial has 9 study locations across District of Columbia, Florida, Michigan, Missouri, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00383149's enrollment target sits among peer trials
58 12th of 32 higher than 21 of 32 other Metastatic Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
RECRUITING · Phase 2
-
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
RECRUITING · Phase 2
-
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia